Screening Neurodevelopmental Disorders by Advanced Practice Nurse in Children Aged 1 to 5 with Congenital Heart Disease

What this Trial Is About

Researchers are evaluating the feasibility and effectiveness of screening for neurodevelopmental disorders NDD in children aged 1 to 5 years with congenital heart disease CHD, a group at high risk for these conditions. This study aims to address a gap in early detection and referral for appropriate care, as over half of children with CHD may develop NDD that can impact their education, social integration, and quality of life. The research is sponsored by the University Hospital in Montpellier and focuses on improving early diagnosis and management in this vulnerable population. The study involves screening children with CHD during their routine cardiac follow-up visits using a screening performed by an Advanced Practice Nurse APN. The screening uses tools such as the Ages & Stages Questionnaires ASQ-3 and the Haute Autorit de Sant HAS identification scale. Children who show signs of possible NDD will be referred to a neuropsychologist for a detailed evaluation and care planning. Those at higher risk due to early cardiac surgery also receive systematic neuropsychological assessments. Participants will be monitored over several months, with the main outcome being the sensitivity of the APN screening to detect NDD confirmed by neuropsychologist assessments within four months. Additional outcomes include feasibility, performance measures like specificity and predictive values, and prevalence of NDD in high-risk children over an 18-month period. The study involves collecting screening results, neuropsychological evaluations, and following childrens neurodevelopment, aiming to improve early identification and intervention strategies.

Feasibility and Efficiency of Screening for Neurodevelopmental Disorders by an Advanced Practice Nurse in Children With Congenital Heart Disease